---

Invasive Ductal Carcinoma (IDC) Right Breast - Stage IIB

Patient: 45-year-old Single Woman

---

SECTION 1: THE DISEASE - WHAT IS IDC?

Definition & Classification

• Robbins, Cotran & Kumar Pathologic Basis of Disease, p. 978
• Schwartz's Principles of Surgery 11th ed, p. 603

Gross & Microscopic Pathology

• Gross: Hard, irregular, stellate mass with gritty, chalky-white desmoplastic stroma; irregular margins on imaging and gross examination
• Microscopy: Irregular nests or sheets of pleomorphic cells invading stroma with exuberant desmoplastic response; necrosis and mitoses common in high-grade tumors
• Some IDC tumors present as well-circumscribed masses (sheets of tumor cells with scant stroma) or as scattered glands infiltrating fibrofatty tissue

---

SECTION 2: RISK FACTORS (Relevant to this 45-year-old woman)

• Bailey and Love's Short Practice of Surgery 28th ed, p. 952

---

SECTION 3: STAGING - TNM SYSTEM (AJCC 8th Edition)

Stage IIB corresponds to:

Primary Tumor (T) Staging

Regional Lymph Nodes - Clinical (cN)

Regional Lymph Nodes - Pathologic (pN)

Distant Metastasis (M)

• M0 = No distant metastasis (this patient's stage)
• M1 = Distant metastasis present

Overall Stage Grouping

• Schwartz's Principles of Surgery 11th ed, p. 603-604

---

SECTION 4: HISTOLOGIC GRADING - NOTTINGHAM SCORE (Elston-Ellis)

Scoring Parameters

Grade Assignment (Total Score 3-9)

• Robbins, Cotran & Kumar Pathologic Basis of Disease, p. 978

---

SECTION 5: BIOMARKER SCORING / RECEPTOR STATUS

Receptor Subtypes and Clinical Implications

HER2 Scoring (FISH/IHC)

Ki-67 Proliferation Index

---

SECTION 6: PROGNOSTIC SCORING TOOLS

1. Oncotype DX (21-Gene RT-PCR Assay)

• Used in ER+/HER2- node-negative patients (and limited use in 1-3 node positive)
• Generates a Recurrence Score (RS):
  • RS 0-10: Low risk - endocrine therapy alone (98.7% recurrence-free at 5 years)
  • RS 11-25: Intermediate - endocrine ± chemotherapy
  • RS >25: High risk - chemotherapy + endocrine therapy

2. MammaPrint (70-Gene Assay)

• FDA approved for Stage 1-2, node-negative, ER+ or ER- tumors
• MINDACT trial: Patients with high clinical risk but low genomic risk had 94.7% distant metastasis-free survival at 5 years without chemotherapy
• Available for FFPE tissue

3. Traditional Prognostic Factors Table

• Schwartz's Principles of Surgery 11th ed, p. 607

---

SECTION 7: WORKUP / INVESTIGATIONS

Triple Assessment (Mandatory)

1. Clinical examination - Lump characteristics (hard, irregular, fixation), nipple changes, skin changes (peau d'orange, ulceration, tethering), axillary LN
2. Imaging:
   • Mammography - Bilateral (two views: craniocaudal + mediolateral oblique)
   • Breast ultrasound - Characterize mass, guide biopsy
   • MRI breast - Assess extent of disease, contralateral breast, lymph nodes
3. Pathology - Core needle biopsy (preferred over excisional biopsy)

Staging Workup for Stage IIB

---

SECTION 8: MANAGEMENT OVERVIEW

1. Tumor size relative to breast size
2. Nodal status
3. Receptor subtype (ER/PR/HER2/TNBC)
4. Patient's wishes, comorbidities
5. BRCA status

---

SECTION 9: PRE-OPERATIVE MANAGEMENT

Clinical Pathway Before Surgery

• Surgeon, medical oncologist, radiation oncologist, pathologist, radiologist, breast care nurse, reconstructive surgeon

Neoadjuvant Chemotherapy (NACT) for Stage IIB

• Downstage tumor to allow breast-conserving surgery (BCS)
• Assess tumor biology and chemosensitivity in vivo
• Eradicate micrometastatic disease

• Breast MRI after 2-3 cycles
• Pathologic Complete Response (pCR) = no residual invasive cancer in breast or LN = excellent prognosis

• Tumor site and axillary LN marked with metal clip before NACT (in case of complete radiologic response)
• Sentinel lymph node identification planned

• Full pre-op assessment: CBC, coagulation, renal/liver function, chest X-ray, ECG
• Cardiac echo (if anthracyclines planned)
• DVT prophylaxis planning
• Blood group & save

• Surgical options: BCS vs. mastectomy
• Breast reconstruction options
• Fertility preservation (patient is 45, premenopausal - ovarian reserve counseling important)
• Lymphedema risk
• Genetic testing

---

SECTION 10: OPERATIVE (INTRA-OPERATIVE) MANAGEMENT

Surgical Options for the Primary Tumor

A. Breast-Conserving Surgery (BCS / Lumpectomy)

• Single tumor with adequate breast-to-tumor ratio
• No multicentric disease
• No diffuse microcalcifications suggesting DCIS
• No BRCA mutation (relative contraindication - prefer mastectomy)
• Tumor >1 cm from skin, >2 cm from nipple
• No prior breast/chest wall radiation
• No SLE or collagen vascular disease

• Remove tumor with 1 cm margin of normal breast tissue
• Orient specimen with sutures: "Long lateral" (L for lateral), Short superior (S for superior)
• Specimen X-ray intraoperatively to confirm excision
• Indelible India ink on specimen surfaces for margin assessment
• Negative margin = "No ink on tumor" (SSO-ASTRO 2014 consensus)
• For DCIS component: minimum 2 mm clear margin required
• Cavity shave if margins are positive
• Volume displacement oncoplasty if >20% breast volume removed

• Multicentric tumor
• Diffuse microcalcifications (DCIS)
• Large tumor-to-breast ratio (volume loss >20%)
• Two positive surgical margins after re-excision
• Prior breast/chest wall radiation
• SLE or connective tissue disease
• Ankylosing spondylitis
• Severe orthopnoea (cannot lie on radiation table)
• Patient preference

B. Mastectomy

• Superior: 2nd rib
• Medial: Parasternal edge
• Inferior: Inframammary crease
• Lateral: Anterior border of latissimus dorsi

• BRCA-positive mutation
• Large tumor relative to breast (no BCS feasible)
• Patient preference for definitive removal
• Multicentric disease

C. Axillary Surgery

• Standard for clinically node-negative patients (cN0)
• Uses dual tracer: blue dye + radioisotope (Tc-99m)
• If 1-2 positive sentinel nodes (SN) AND patient is undergoing BCS with whole-breast irradiation (WBI): ALND can be omitted (ACOSOG Z0011 trial - no OS or DFS difference)
• If ≥3 positive SNs, or SNs positive in mastectomy setting: ALND required

• Removes Level I, II, III axillary nodes
• Required for: clinically node-positive (cN2/N3), >2 positive SNs in mastectomy, or when SLNB fails
• Morbidity: lymphedema (~13% in ALND vs ~2% in SLNB alone), wound infection, seroma, paresthesias

• If N+ at diagnosis and converts to cN0 after NACT: Targeted SLNB using clipped nodes (marked pre-NACT with metal clip + India ink)
• Minimum 3 sentinel nodes should be removed; dual tracer used
• False-negative rate >10% if standard SLNB alone

D. Breast Reconstruction (if mastectomy performed)

• Bailey and Love's 28th ed, p. 957-960
• Schwartz's Principles of Surgery 11th ed, p. 816-832

---

SECTION 11: POST-OPERATIVE MANAGEMENT

A. Adjuvant Chemotherapy

• Node-positive disease
• Triple-negative subtype
• HER2-positive subtype
• High Oncotype DX score (>25)
• High Ki-67, Grade 3
• Premenopausal ER+ with high risk features

• TNBC with residual: Capecitabine (CREATE-X trial) for 6-8 cycles
• HER2+ with residual: T-DM1 (trastuzumab emtansine) for 14 cycles

B. Adjuvant Radiotherapy (RT)

• ALL patients who had BCS (mandatory)
• Post-mastectomy if: T3/T4, N1-N3, ≥4 positive LN, positive/close margins

• Whole breast (after BCS)
• Chest wall + supraclavicular + axillary nodal region (post-mastectomy)
• Internal mammary chain if medial tumor or N2b
• Boost to tumor bed (10-16 Gy) if high-grade or close margins

• Conventional: 50 Gy in 25 fractions over 5 weeks + boost
• Hypofractionation: 40 Gy in 15 fractions (equivalent efficacy, fewer visits)
• Reduces locoregional recurrence and improves survival

C. Adjuvant Endocrine (Hormonal) Therapy

D. Adjuvant Targeted Therapy

E. Post-Operative Wound Care & Early Recovery

• Drains: Jackson-Pratt or Blake drains placed; removed when output <30 mL/day
• Arm mobilization: Gentle shoulder exercises from Day 1-2
• Wound inspection: Daily dressing changes; suture/staple removal at 10-14 days
• DVT prophylaxis: LMWH + compression stockings for high-risk patients
• Seroma management: Aspiration if symptomatic
• Lymphedema counseling: Avoid BP cuff, blood draws, cuts on ipsilateral arm
• Pain control: Regular paracetamol ± NSAIDs; opioids if needed

F. Surveillance & Follow-Up

---

SECTION 12: SPECIAL CONSIDERATIONS FOR THIS PATIENT

She is 45, Premenopausal, Single

---

SECTION 13: KEY LANDMARK TRIALS REFERENCED

---

SUMMARY MANAGEMENT ALGORITHM FOR THIS PATIENT

45yo woman, IDC Right Breast Stage IIB
          ↓
TRIPLE ASSESSMENT + FULL STAGING WORKUP
          ↓
MDT Discussion
          ↓
ER/PR/HER2/Ki-67 / Oncotype DX (if ER+/HER2-)
          ↓
┌─────────────────────────────────────┐
│    Is BCS feasible upfront?         │
│    (Tumor size vs breast size,      │
│    single lesion, no contraindics)  │
└─────────────────────────────────────┘
       ↓ YES              ↓ NO (large tumor, BRCA+)
  Upfront Surgery    NACT first → Downstage
  BCS + SLNB         AC × 4 → T × 4 (±trastuzumab if HER2+)
       ↓                    ↓
Post-op RT             Re-assess with MRI
Adjuvant chemo         → BCS or MRM + axillary surgery
Endocrine Rx
±Targeted Rx

POST-OP: RT + Endocrine Rx + Targeted Rx + Surveillance
Genetic counseling + Fertility counseling
Psychological support

---

---

INVASIVE DUCTAL CARCINOMA (IDC) - RIGHT BREAST, STAGE IIB

Patient: 45-Year-Old Single Woman - Comprehensive Clinical Guide

---

SECTION 1: THE DISEASE - INVASIVE DUCTAL CARCINOMA

Definition

• Schwartz's Principles of Surgery 11th ed, p. 603
• Robbins, Cotran & Kumar Pathologic Basis of Disease, p. 978

Epidemiology

• Breast cancer is the most frequent cancer among women: 2.3 million new cases worldwide in 2020, representing ~25% of all cancers in women
• Incidence: 27/100,000 in Middle Africa vs. 92/100,000 in North America
• In Western Europe: ~1 in 9 women will develop breast cancer
• Lifetime risk for an American woman: 1 in 8
• 75% of breast cancers are diagnosed after age 50 (this patient at 45 is relatively young)
• ~12% of all breast cancers are caused by germline mutations; BRCA1/BRCA2 account for half
• Bailey and Love's Short Practice of Surgery 28th ed, p. 952
• Robbins & Kumar Basic Pathology, p. 719

Histopathology

Classification of Invasive Breast Cancer (Foote & Stewart)

• Schwartz's Principles of Surgery 11th ed, p. 603

---

SECTION 2: RISK FACTORS

---

SECTION 3: TRIPLE ASSESSMENT

---

SECTION 4: BI-RADS SCORING SYSTEM

Background

BI-RADS Breast Composition Categories (Density)

• Fischer's Mastery of Surgery 8th ed, p. 1406

BI-RADS Assessment Categories - COMPLETE TABLE

• Bailey and Love's Short Practice of Surgery 28th ed - Table 58.1, p. 938
• Fischer's Mastery of Surgery 8th ed - Table 52.3, p. 1409

This patient's imaging: A solid, irregular-shaped mass, taller than wider, with angular/spiculated irregular margins on ultrasound = BI-RADS 5 → Requires biopsy / surgical treatment. Once biopsy confirms IDC, the category upgrades to BI-RADS 6 throughout the pre-operative/NACT phase.

Mammographic & Ultrasound Features of Breast Carcinoma

When to Use MRI of Breast

• Dense breasts or discordant/equivocal mammogram/US findings
• Distinguish scar from recurrence after BCS
• Assess extent before surgery / contralateral breast assessment
• Monitor response to NACT
• BRCA-positive women (annual screening)
• Any abnormality on MRI not seen on mammography requires focused ultrasound

---

SECTION 5: TNM STAGING (AJCC 8th Edition)

Stage IIB = T2N1M0 or T3N0M0

Primary Tumor (T)

Regional Lymph Nodes - Clinical (cN)

Regional Lymph Nodes - Pathologic (pN)

Distant Metastasis (M)

• M0 = No clinical/radiographic distant metastasis
• cM0(i+) = Circulating tumor cells detected, no clinical metastasis
• M1 = Distant metastasis

Overall Stage Grouping

• Schwartz's Principles of Surgery 11th ed, p. 603-604

---

SECTION 6: HISTOLOGIC GRADING - NOTTINGHAM HISTOLOGIC SCORE (Elston-Ellis)

Scoring

Grade Assignment

• Robbins, Cotran & Kumar Pathologic Basis of Disease, p. 978

---

SECTION 7: RECEPTOR / BIOMARKER STATUS - MOLECULAR SUBTYPES

Receptor Testing (Every IDC Must Have This)

HER2 IHC Scoring

Molecular Subtypes

---

SECTION 8: PROGNOSTIC SCORING TOOLS

1. Oncotype DX (21-Gene RT-PCR Assay)

2. MammaPrint (70-Gene Assay)

• Low genomic risk despite high clinical risk: 94.7% distant metastasis-free survival at 5 years without chemotherapy (MINDACT trial)
• Available for FFPE tissue

3. Traditional Prognostic Factors

• Schwartz's Principles of Surgery 11th ed, p. 607

---

SECTION 9: INVESTIGATIONS / WORKUP SUMMARY

Full Pre-Treatment Workup for Stage IIB

---

SECTION 10: PRE-OPERATIVE MANAGEMENT

A. Multidisciplinary Team (MDT) Discussion - Mandatory

B. Neoadjuvant Chemotherapy (NACT)

• Downstage tumor to convert to BCS-eligible
• Assess in-vivo chemosensitivity
• Eradicate occult micrometastases early
• pCR = excellent prognostic marker

C. Pre-NACT Preparations

• Metal clip placed in tumor and any positive axillary LN (targeted SLNB post-NACT)
• Permanent India ink tattoo of positive LN if clip not available
• Oncofertility referral: Embryo/oocyte cryopreservation before NACT starts
• Baseline echo (anthracycline cardiotoxicity)
• BRCA testing result must be available before surgery planning

D. Anaesthetic Pre-operative Assessment

• CBC, coagulation profile, renal/hepatic function, blood sugar
• Chest X-ray, 12-lead ECG
• Blood group and screen
• DVT risk stratification (Caprini score) → LMWH + compression stockings plan
• Lung function if indicated
• Nutritional assessment

E. Patient Counseling Before Surgery

• Choice between BCS and mastectomy
• Reconstruction options (immediate vs. delayed)
• Sentinel node biopsy vs. ALND
• Lymphedema risk and prevention
• Chemotherapy side-effects (alopecia, nausea, fatigue, premature menopause)
• Fertility implications
• Psychological support / body image
• Genetic testing results discussion

---

SECTION 11: OPERATIVE (INTRA-OPERATIVE) MANAGEMENT

Decision Matrix: BCS vs. Mastectomy

A. Breast-Conserving Surgery (BCS / Lumpectomy / WLE)

1. Mark tumor site preoperatively (wire-guided or radioactive seed localization if impalpable)
2. Place curvilinear/concentric incision in upper breast; radial incisions in lower breast
3. Excise tumor with 1 cm margin of normal breast tissue
4. Orient specimen: Long suture = Lateral ("L for Lateral"); Short suture = Superior ("S for Superior")
5. Intraoperative specimen X-ray to confirm excision
6. Apply indelible India ink to all specimen surfaces
7. Negative margin = "No ink on tumor" (SSO-ASTRO 2014 consensus: wider margins do not reduce IBTR in invasive cancer)
8. For any DCIS component: minimum 2 mm clear margin required
9. If margin involved → cavity shave re-excision
10. Volume loss ≤20%: Direct tissue approximation with absorbable sutures
11. Volume loss >20% → Oncoplastic procedure required

• Multicentric tumor
• Diffuse microcalcifications on mammogram
• Large tumor-to-breast ratio
• Two positive surgical margins after re-excision
• Previous breast/chest wall radiation
• SLE or connective tissue disease
• Ankylosing spondylitis
• Severe orthopnoea (cannot lie on radiation table)
• Patient preference

B. Mastectomy

• Superior: 2nd rib (where anterior premammary fascia fuses with posterior pectoral fascia)
• Medial: Parasternal edge
• Inferior: Inframammary crease
• Lateral: Anterior border of latissimus dorsi

C. Axillary Surgery

• Dual tracer: patent blue dye + Tc-99m radioisotope
• First draining node(s) from primary tumor
• If 1-2 positive SNs + BCS + whole-breast irradiation (WBI): ALND omitted - ACOSOG Z0011 trial showed no difference in OS (91.9% vs 92.5%) or DFS (82.2% vs 83.8%) at 6-year follow-up
• ALND still required if: ≥3 positive SNs, positive SN with mastectomy, clinically node-positive

• Requires ≥3 sentinel nodes removed
• Dual tracers mandatory
• Clipped node must be identified and removed
• Standard SLNB alone has false-negative rate >10%; targeted technique reduces this

• Removes Level I, II, III nodes
• Complications: Lymphedema (13% ALND vs 2% SLNB alone), wound infection, seroma (7.1%), axillary hematoma (1.4%), paresthesias (8.6%), reduced shoulder range of motion

D. Breast Reconstruction

• Bailey and Love's 28th ed, p. 957-962

---

SECTION 12: POST-OPERATIVE MANAGEMENT

A. Immediate Post-Op (Ward Management)

B. Pathology Report Assessment

• Tumor size (pathologic T)
• Grade (Nottingham score)
• Margins status (distance to nearest inked margin)
• Number of nodes examined / positive nodes
• Lymphovascular invasion (LVI)
• Pathologic stage (ypTNM if post-NACT)
• Pathologic Complete Response (pCR): No residual invasive cancer in breast or nodes

C. Adjuvant Radiotherapy (RT)

• Conventional: 50 Gy in 25 fractions × 5 weeks + boost
• Hypofractionation: 40 Gy in 15 fractions (equivalent efficacy, fewer visits)

D. Adjuvant Chemotherapy

E. Adjuvant Endocrine (Hormonal) Therapy

F. Adjuvant Targeted Therapy

G. Surveillance Schedule

---

SECTION 13: SPECIAL CONSIDERATIONS FOR THIS 45-YEAR-OLD SINGLE WOMAN

---

SECTION 14: KEY LANDMARK TRIALS

---

QUICK REFERENCE SUMMARY CARD

PATIENT: 45yo woman | Right IDC | Stage IIB (T2N1M0 or T3N0M0)
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
IMAGING          → BI-RADS 5 (mammogram/US) → Core biopsy → BI-RADS 6
STAGING WORKUP   → CT CAP + Bone scan + ER/PR/HER2/Ki-67 + BRCA
MDT DECISION     → NACT if large/HER2+/TNBC | Upfront surgery if BCS-eligible
NACT             → AC × 4 → T × 4 (±trastuzumab if HER2+)
SURGERY          → BCS (if downstaged) or MRM | SLNB ± ALND
POST-OP RT       → Whole breast (BCS) or chest wall + nodes (mastectomy)
CHEMO            → Per molecular subtype + pCR status
ENDOCRINE        → Tamoxifen ± OFS (premenopausal, ER+)
TARGETED         → Trastuzumab (HER2+) | Olaparib (BRCA+) | Abemaciclib (HR+N+)
SURVEILLANCE     → 3-6 monthly × 3 yrs → annual lifelong + mammography
SPECIAL          → Fertility preservation | BRCA counseling | Psycho-oncology
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

---

• Bailey and Love's Short Practice of Surgery 28th Edition (Tables 58.1, 58.3; pp. 938-963)
• Schwartz's Principles of Surgery 11th Edition (Tables 17-10, 17-12; pp. 579-832)
• Fischer's Mastery of Surgery 8th Edition (Tables 52.2, 52.3; pp. 1406-1718)
• Robbins, Cotran & Kumar Pathologic Basis of Disease (pp. 978-985)
• Robbins & Kumar Basic Pathology (p. 719)